Arvind Krishna, MD
Endocrinology, Diabetes & Metabolism · Canton, OHNPI 1275579542
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by Insulet Corporation at 26.6% of the total. Reporting peaked in 2020 at $2,665 and has fallen 75.4% since, to $656 in 2025.
Across 240 payments — averaging $40.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$3K
- Biogen$2K
- AbbVie$1K
- Novo Nordisk$358
- Corcept Therapeutics$290
- Amgen$252
- plus $3K from 42 others
Across 3,023 payments — averaging $1024.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.7M
- Novo Nordisk AS$606K
- Amgen$206K
- Genentech, Inc.$132K
- Bayer$115K
- Boehringer Ingelheim$110K
- plus $261K from 7 others
What the payments were for
- Speaking & faculty fees$2,40025%
- Travel & lodging$2,67128%
- Food & beverage$4,28544%
- Education$2833%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$2,400
How this compares
$9,640 in reported general payments places this provider in the 80th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SomavertPegvisomant | 13 | $242,469 |
| JardianceEmpagliflozin | 218 | $199,461 |
| TrulicityDulaglutide | 90 | $110,187 |
| OzempicSemaglutide | 72 | $71,041 |
| TradjentaLinagliptin | 72 | $52,501 |
| FarxigaDapagliflozin Propanediol | 57 | $45,992 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $41,133 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $31,939 |
| JanuviaSitagliptin Phosphate | 42 | $31,392 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $29,578 |
| MounjaroTirzepatide | 22 | $29,525 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $24,648 |
| Humalog Kwikpen U-100Insulin Lispro | 71 | $21,676 |
| Novolog FlexpenInsulin Aspart | 66 | $18,958 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $18,285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $99 | $251,962290 claims |
| PfizerSomavert | $63 | $242,46913 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $243 | $145,546133 claims |
| Novo NordiskOzempic | $358 | $71,04172 claims |
| AstraZenecaFarxiga | $63 | $45,99257 claims |
| MerckJanuvia | $12 | $31,39242 claims |
| AbbVieSynthroid, Armour Thyroid | $1,489 | $16,533293 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $45 | $6,600745 claims |
| IBSA Pharma Inc.Tirosint | $75 | $2,92213 claims |
| Sanofi-aventis U.S. LLCLantus | $224 | $1,53316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Canton
- Kevin WietechaCanton$127K
- Elena ChristofidesColumbus$2.3M
- Kevin PantaloneCleveland$1.2M
- John PaesWesterville$671K
- Samuel AndersonColumbus$556K
- Bhaskar GundaboluToledo$471K
- Nelson WattsCincinnati$346K
- Baker MachhadiehHamilton$304K
- Brian BurtchMentor$264K
- Allan KennedyCleveland$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.